Immunogenicity of SARS-CoV: The receptor-binding domain of S protein is a major target of neutralizing antibodies

Advances in Experimental Medicine and Biology

Volumn 581, Issue , 2006, Pages 539-542

  He, Yuxian ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934442724     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-33012-9_98     Document Type: Conference Paper

References (14)

1. P. A. Rota, M. S. Oberste, S. S. Monroe, et al., Characterization of a novel coronavirus associated with severe acute respiratory syndrome, Science 300, 1394 (2003).
2. S. K. Wong, W. Li, M. J. Moore, H. Choe, and M. Farzan, A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2, J. Biol. Chem. 279, 3197 (2004).
3. S. Liu, G. Xiao, Y. Chen, et al., Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors, Lancet 363, 938 (2004).
4. Y. He and S. Jiang, Vaccine design for severe acute respiratory syndrome coronavirus, Viral Immunol. 18, 327 (2005).
5. S. Jiang, Y. He, and S. Liu, SARS vaccine development, Emerg. Infect. Dis. 11, 1016 (2005).
6. Z. Y. Yang, W. P. Kong, Y. Huang, et al., A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice, Nature 428, 561 (2004).
7. H. Bisht, A. Roberts, L. Vogel, et al., Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice, Proc. Natl. Acad. Sci, USA 101, 6641 (2004).
8. A. Bukreyev, E. W. Lamirande, U. J. Buchholz, et al., Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS, Lancet 363, 2122 (2004).
9. Y. Nie, G. Wang, X. Shi, et al., Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection, J. Infect. Dis. 190, 1119 (2004).
10. Y. He, H. Lu, P. Siddiqui, Y. Zhou, and S. Jiang, Receptor-binding domain of SARS coronavirus spike protein contains multiple conformational-dependant epitopes that induce highly potent neutralizing antibodies, J. Immunol. 174, 4908 (2004).
11. Y. He, Y. Zhou, P. Siddiqui, and S. Jiang, Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry, Biochem. Biophys. Res. Commun. 325, 445 (2004).
12. Y. He, Y. Zhou, H. Wu, B. Luo, J. Chen, W. Li, and S. Jiang, Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines, J. Immunol. 173, 4050 (2004).
13. Y. He, Y. Zhou, S. Liu, Z. Kou, W. Li, M. Farzan, and S. Jiang, Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine, Biochem. Biophys. Res. Commun. 324, 773 (2004).
14. Y. He, Q. Zhu, S. Liu, Y. Zhou, B. Yang, J. Li, and S. Jiang, Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines, Virology 334, 74 (2005).